3000 PEGASUS PARK DRIVE, DALLAS, TX
Reports Full-Year 2025 Financial Results and Provides Corporate Update
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News, Articles of Incorporation
Amended material disclosure
FY 2025
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership